Reaffirms FY25 gross profit view $73M-$82M. Reaffirms FY25 free cash flow view (21M)-(12M). The company also continues to see FY25 adjusted EBITDA of (17M)-(8M). The company adds that given revenue growth in the first half of the year, it currently believes it can reach the higher-end of the revenue guidance range for 2025. CEO Daniel Virnich commented, “The momentum we’re seeing in new contract signings, combined with continued strength in pharmacy, gives us increasing confidence that we’ll achieve revenue at the high end of our guidance range for the year and achieve adjusted EBITDA positivity as we exit 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOI:
- Oncology Institute reports Q2 EPS (15c) vs. (17c) last year
- Oncology Institute Inc options imply 16.2% move in share price post-earnings
- Three new option listings and one option delisting on July 24th
- Oncology Institute initiated with an Outperform at Noble Capital
- Oncology Institute initiated with a Buy at B. Riley